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Whilestudiesinthepasthavefocusedmoreontreatmentofthemanicphaseofbipolardisorder(BD),recentﬁndingsdemonstrate
the depressive phase to be at least as debilitating. However, in contrast to unipolar depression, depression in bipolar patients
exhibits a varying response to antidepressants, raising questions regarding their eﬃcacy and tolerability. Methods.W ec o n d u c t e da
MEDLINE and Cochrane Collaboration Library search for papers published between 2005 and 2011 on the subject of antidepres-
sant treatment of bipolar depression. Sixty-eight articles were included in the present review. Results. While a few studies did advo-
cate the use of antidepressants, most well-controlled studies failed to show a robust eﬀect of antidepressants in bipolar depression,
regardless of antidepressant class or bipolar subtype. There was no signiﬁcant increase in the rate of manic/hypomanic switch,
especially with concurrent use of mood stabilizers. Prescribing guidelines published in recent years rely more on atypical anti-
psychotics, especially quetiapine, as a ﬁrst-line therapy. Conclusions. Antidepressants probably have no substantial role in acute bi-
polar depression. However, in light of conﬂicting results between studies, more well-designed trials are warranted.
1.Introduction
Bipolardisorder(BD)isadevastatingillness,carryinganim-
mense burden of both morbidity [1] and all-cause mortality
[2],includinghighratesofcompletedsuicide[3].Withalife-
time prevalence of 1.5–2% in Europe [4] and a similar pre-
valence in the USA [5], much attention has been drawn to
assessing potential treatments for alleviating the symptoms
of this condition, manic and depressive alike. However, while
clinical focus in the past tended to be more on the manic
phase of the disorder, recent ﬁndings illustrate the need to
focus on eﬀective treatment strategies for the depressive
phase, for several reasons. First, observations of the natural
course of BD show the considerable amount of time spent in
the depressive phase compared to the manic phase (30% on
average compared to 10% in bipolar 1 disorder) [6], lead-
ing to severe morbidity, including a marked occupational
impairment [7]. Second, the depressive phase of BD is more
prone to suicide [8]. Incomplete remission, with enduring
subsyndromal depressive symptoms, has been demonstrated
bothtocausefunctionalimpairment[9]andincreasetherisk
of relapse [10], emphasizing the importance of optimizing
the treatment for the depressive phase of BD.
Since their conception, antidepressants have been the
mainstay of treatment for depression of any kind; to this day,
antidepressants are prescribed to patients suﬀering from
bipolar depression in 50% of cases [11]. However, observa-
tions regarding questionable eﬃcacy and tolerability of anti-
depressants in bipolar depression have prompted a huge
debate on the topic in recent years. We, therefore, wished to
review the latest articles addressing the role of antidepres-
sants in the pharmacological treatment of acute bipolar dep-
ression.
2. Methods
We conducted a MEDLINE and Cochrane Collaboration
Library search for any English-language articles published
from January 1st 2005 to August 31st 2011, containing the
keywords“treatment,”“bipolar,” and“depression” inthetitle2 Depression Research and Treatment
orabstract.Thesearchincludedclinicaltrials,meta-analyses,
review articles, practice guidelines, conference summaries,
editorials, and comments. We further used the “related
citation” property for each item to search for other pertinent
articles.
Initial screening yielded 1,062 results. Abstracts were
then reviewed to exclude articles of low relevance, such as
those regarding treatments other than antidepressants or
concerning patients whose age is above 65 or below 18 years.
A total of 68 items were ﬁnally included in the review.
3. Results
3.1. Antidepressant Monotherapy
3.1.1. Antidepressant Monotherapy for Bipolar I Disorder
Fluoxetine. In light of evidence of an increased risk of manic
induction resulting from unopposed antidepressant treat-
ment in bipolar I disorder [12], there has been a scarcity of
studies in recent years examining the role of antidepressant
monotherapy in bipolar I depression. In a 2005 randomized
clinical trial consisting of 34 bipolar patients, 32 of which
of the bipolar I subtype, treatment with 10–30mg of ﬂu-
oxetine showed comparable results to treatment with either
olanzapine or an olanzapine-ﬂuoxetine combination. Over
the course of the 8-week trial, a signiﬁcant reduction in
both HAM-D 28 and MADRS ratings was observed, with no
evidence of an increase in treatment-emergent manic symp-
toms, as measured by the Young Mania Rating Scale (YMRS)
[13].
Paroxetine. In the 2010 EMBOLDEN II study, a total of 740
depressedbipolarpatients(478bipolarI,262bipolarII)were
treated by monotherapy with either paroxetine (20mg/d),
quetiapine (300mg/d or 600mg/d), or placebo. An eight-
week followup revealed no statistically signiﬁcant change in
MADRS total score for paroxetine compared with placebo,
both in bipolar I and bipolar II patients, in contrast with
a marked response observed in the quetiapine arm. Manic/
hypomanicswitchrates,deﬁnedasYoungManiaRatingScale
(YMRS) ≥16, did not statistically diﬀer between paroxetine
and placebo (10.7% and 8.9%, resp.) [14], rendering paroxe-
tine a safe, yet not an eﬃcacious, option as monotherapy for
bipolar depression.
3.1.2. Antidepressant Monotherapy for Bipolar II Disorder
Fluoxetine. Concernsabouttheriskofmanicinductionhave
prompted studies of antidepressant monotherapy in recent
years to focus on bipolar II patients, where the risk has
been estimated to be lower. One large study examining the
response to antidepressant monotherapy in BP II patients
included a 14-week open-label trial of 148 patients, treated
by 10–80mg ﬂuoxetine daily. Response rate was demonstra-
ted to be 59.5% (95% CI, 51.1%–67.4%, P<0.0005) and
remission rate 58.1% (95% CI, 49.7%–66.2%, P<0.0005).
4.1% of patients had treatment-emergent hypomania,
deﬁned as YMRS score of 8 or greater (95% CI, 1.5%–8.6%,
P<0.0005), while 2.7% (95% CI, 0.7%–6.8%, P<0.0005)
hadaYMRSscoreof12orgreater.19.6%ofpatientshadsub-
syndromal hypomania (95% CI, 13.5%–26.9%, P<0.0005),
deﬁned as an episode lasting 3 or less days with 4 symptoms
ormore,orasanepisodelasting4daysormorewith3symp-
toms or less. Although one patient had treatment-emergent
mania, reexamination of his medical record revealed a
diagnosis of BP I disorder, rather than BP II. The authors
concluded by deeming ﬂuoxetine monotherapy a safe and
eﬀective short-term treatment of bipolar II depression, with
a relatively low syndromal mood conversion rate [15].
Escitalopram. In a small, randomized, placebo-controlled
proofofconceptstudy(n = 10),treatmentwithescitalopram
demonstrated a signiﬁcant improvement in the depressive
symptoms and functioning status of BPII patients over nine
months, with no evidence of an aﬀect switch, leading the
author to suggest SSRIs as “mood stabilizers for Bipolar II
Disorder” [16].
Venlafaxine. In a randomized open-label clinical trial in-
cluding 83 BPII patients, 43 were randomized to treatment
with venlafaxine and 40 to lithium monotherapy. Following
a 12-week observation period, venlafaxine surpassed lithium
both in response rates (58.1% versus 20.0%; P<0.0005) and
in remission rates (44.2% versus 7.5%; P<0.0005), with no
signiﬁcant increase in mean YMRS scores [17]. A secondary
analysis of the data showed no diﬀerence in treatment res-
ponse between rapid and nonrapid cyclers [18]. Switch to
venlafaxine treatment for lithium nonresponders resulted in
a signiﬁcant improvement in depressive symptoms, with no
evidence of manic induction over a follow-up period of 12
weeks[19].Anothersmallerstudyofﬁfteendepressedfemale
patients with a diagnosis of BPII disorder corroborated these
ﬁndings, demonstrating no episodes of drug-induced mania
or hypomania during 6 weeks of venlafaxine monotherapy
[20].
Tricyclic Antidepressants and Monoamine Oxidase Inhibitors.
In a 2007 randomized controlled trial, 70 BP II patients were
treated with the tricyclic antidepressant imipramine (aver-
age dose 250mg/d) or the monoamine oxidase inhibitor
phenelzine (average dose 60mg/d), showing a response rate
of 57% and 52%, respectively, compared with 23% in the
placebo arm. Data regarding statistical signiﬁcance was lack-
ing.Althoughtherewasnoevidenceofmanicinduction[21],
these results are limited, as no valid tool was used to assess
treatment-emergent manic/hypomanic symptoms.
3.2. Antidepressants as Adjuncts to Mood Stabilizers
3.2.1. Eﬃcacy and Tolerability. In a meta-analysis of 12 trials
encompassing a total of 1,088 patients, published in 2004 by
Gijsman et al. [22], antidepressants of the selective serotonin
reuptake inhibitor class (SSRIs), tricyclic antidepressants
(TCAs), and monoamine oxidase inhibitors (MAOIs) were
demonstrated to be eﬀective as adjuncts to mood stabilizers
in the treatment of acute bipolar depression. Analysis of fourDepression Research and Treatment 3
randomizedcontrolledtrials,consistingof662patients,most
of them treated by concurrent mood stabilizers, has shown
a signiﬁcant advantage in achieving response for the group
treated with an antidepressant (ﬂuoxetine, imipramine, or
the MAOIs tranylcypromine and selegiline) compared to
placebo (risk ratio = 1.86, 95% CI = 1.49–2.30), with a
number needed to treat (NNT) of 4.2 (95% CI = 3.2–6.4).
Patients treated with an antidepressant (paroxetine, imip-
ramine, or ﬂuoxetine) were also more likely to reach remis-
sion than those who were not taking an antidepressant (risk
ratio = 1.41, 95% CI = 1.11–1.80), with an NNT of 8.4 (95%
CI = 4.8–33). The risk of manic switch following the use
of SSRIs was 3.2%, not signiﬁcantly greater than placebo;
however, the authors stated that the low incidence of manic
events over a short follow-up period of four to ten weeks
limits the power to detect a signiﬁcant diﬀerence. The rate of
manic switch following the use of TCAs was demonstrated
to be as high as 10%, an absolute risk diﬀerence of 6.8%
(95% CI = 1.7%–11.9%); however, no valid scales were used
to assess manic symptoms, causing a problem with data in-
terpretation (see Section 3).
The authors concluded that SSRIs may be an eﬀective
treatment for acute bipolar depression, with a low risk of
manic switch early in the course of treatment.
Although the recommendation to use antidepressants as
adjunctstomoodstabilizersinthetreatmentofacutebipolar
depression did not conﬂict with common practices at
the time, as reﬂected in the 2003 British Association for
Psychopharmacology guideline [23], it was “at odds” with
the American Psychiatric Association (APA) guideline, pub-
lished in April 2002, where lithium or lamotrigine was re-
commended as a ﬁrst-line agent [24]. The meta-analysis
received many comments, concerning the short duration of
studies [25], the heterogeneous inclusion of patients with
bipolarIIdepressionormixedepisodes,andtheconcomitant
use of a mood stabilizer in the majority of patients, allegedly
responsible for the low rate of manic switch observed [26].
Over the course of the next few years, numerous trials
and meta-analyses sought to clarify the question of the role
of antidepressants as adjuncts to mood stabilizers in the
acute treatment of bipolar depression. One small double-
blind randomized trial (n = 20) compared the addition of
lamotrigine versus citalopram to treatment with a mood sta-
bilizer in bipolar depressed patients; though both treatments
demonstrated a signiﬁcant decrease in MADRS scores after
six weeks of treatment with no evidence of major adverse
events, the lack of a placebo arm and the small sample size
limit the applicability of the data [27]. A similar size open-
label trial of 12-week addition of escitalopram to treatment
with mood stabilizer showed comparable results, including
a mean decrease in HAM-D score of 12 points (P<. 001).
Although three cases of mania/hypomania were described,
the small sample size and lack of control represent a problem
with data interpretation [28].
Perhapsoneofthemostquotedstudiesonthetopicisthe
2007 trial conducted by the Systematic Treatment Enhance-
ment Program for Bipolar Disorder (STEP-BD) collabora-
tors, published in the New England Journal of Medicine
by Sachs et al. [29]. In this double-blinded, randomized
controlled trial of 366 Bipolar I and II patients, subjects
receiving treatment with a mood stabilizer were randomized
to cotreatment with an SSRI antidepressant, either bupro-
pion or paroxetine. The duration of followup was 26 weeks,
and the primary outcome was deﬁned as at least 8 consec-
utive weeks of euthymia. However, contrary to the ﬁndings
presented by Gijsman et al. [22], the study did not ﬁnd a
signiﬁcant eﬀect of either SSRI in any parameter, including
remission or response. The reason for this disparity, as sug-
gested by the authors, may lie in the more naturalistic design
of the trial, allowing inclusion of patients with various com-
orbidities, such as anxiety disorders, substance abuse, or
psychotic symptoms, as well as those receiving additional
pharmacotherapy or psychotherapy [29]. As was the case in
the previous meta-analysis by Gijsman et al. [22], SSRIs did
not show an increased risk of manic switch when coadminis-
tered with a mood stabilizer. However, further retrospective
analysis of the risk of a manic switch, based on self-report,
didrevealanincreasedriskofswitch,correlatingwithashor-
ter duration of illness and a history of multiple antidepres-
sant trials [30]. In a diﬀerent trial assessing the risk of switch,
bipolar subtype was also demonstrated to correlate with the
risk of treatment-emergent mania/hypomania, with patients
diagnosed with the bipolar II subtype showing signiﬁcantly
less susceptibility to switch (12% and 2%, resp.; YMRS > 14)
[31].
In a recent meta-analysis by Sidor and MacQueen [32],
six trials comparing antidepressants to placebo in the acute
(4–16 weeks) treatment of depressed bipolar I or II patients
were analyzed [13, 29, 33–37]; 68% of patients were treated
byconcomitantmoodstabilizers.Althoughtheeﬀectofanti-
depressants was nonsigniﬁcant compared to placebo in
induction of clinical response (95% CI 0.99–1.40; P = .06),
the authors pointed out the heterogeneity of the studies,
which was assigned to the largest trial—published by Sachs
et al. [29]—showing a negative treatment eﬀect, favoring
placebo. Analyzing for clinical remission showed similar
results, also failing to show a signiﬁcant beneﬁt of antide-
pressants over placebo (95% CI 0.98–1.47; P = .09). Rates of
switch to mania/hypomania by using a Young Mania Rating
Scale (YMRS) threshold of 12 were 7.7% for antidepressants
and 7.2% for placebo, a non-signiﬁcant diﬀerence (RR =
0.97; 95% CI 0.62–1.53; P = .90). When discussing the
discordance between the results of this meta-analysis and the
one published by Gijsman et al. [22], the authors stated that
two of the four trials used in the aforementioned analysis,
favoring antidepressants (published in 1982 and 1980 by
Himmelhoch et al. [38] and Mendlewicz and Youdim [39],
resp.), did not properly diﬀerentiate between bipolar and
unipolar depression, causing marked bias towards antide-
pressant eﬃcacy [32].
3.2.2. Comparison of Drug Classes: SSRIs, SNRIs, and TCAs.
In addition to the general question regarding the eﬃcacy and
tolerability of antidepressants in the treatment of bipolar
depression, several studies in recent years have attempted
to compare the individual properties of various antidepres-
sants.Amongthemisthe2006publicationbyPostetal.[40],
comparing a randomized addition of venlafaxine, sertraline,4 Depression Research and Treatment
or bupropion to maintenance treatment with lithium during
treatment-emergent depression. Of the 174 patients enrolled
in the study, 49–53% demonstrated a response to treatment
while 34–41% reached remission after 10 weeks, using the
Inventory of Depressive Symptomatology (IDS) and Clinical
Global Impression for Bipolar Disorder (CGI-BP) scales.
There was no signiﬁcant diﬀerence in eﬃcacy between drug
classes. Manic switch, using a YMRS threshold score of 13,
ensued in 4% of patients on bupropion, 7% of patients on
sertraline, and 15% on venlafaxine, with a nonsigniﬁcant
trend towards venlafaxine being more harmful (P = 0.052).
Adding a more liberal criterion of manic switch, such as a
CGI-BP severity of mania ≥3, yielded a signiﬁcant diﬀerence
between drug classes, with venlafaxine showing a higher risk
of switch than both sertraline or bupropion (P = 0.03);
however, the lack of a placebo arm seriously under-powers
this study. Interestingly, the higher risk of manic switch in
the venlafaxine group was accounted for by the rapid-cycling
subset of patients, which constituted 27% of the sample,
showing particular sensitivity to manic switch following
venlafaxine treatment.
Another recent comparison of antidepressant classes as
adjuncts to mood stabilizers is the 2010 randomized clinical
trial published by Pilhatsch et al. [41]. Forty depressed bipo-
lar I and II patients, on maintenance treatment with lithium,
were randomized to receive either adjunctive paroxetine or
amitriptyline. Following a six-week follow-up period, both
treatments were shown to be equally as eﬀective, with no
signiﬁcant diﬀerence in HAM-D reduction (−14.9 versus
−15.5; P = 0.798) or ﬁnal HAM-D21 score (8.2 versus 9.9;
P = 0.420) between paroxetine and amitriptyline, respec-
tively. Treatment with paroxetine did show a signiﬁcantly
more rapid onset, evident since the third week of treatment.
While one patient treated with paroxetine had treatment
emergent hypomania, fewer adverse events were recorded
for the group treated with paroxetine than for amitriptyline,
with an emergent symptom index of 4.1 and 5.0 per patient
in each group, respectively, making paroxetine a better over-
all ﬁrst choice of the two.
A more intricate look into the potential use of antide-
pressants as adjuncts to treatment is a comparative trial em-
ploying lithium, lamotrigine, and paroxetine in two diﬀerent
treatmentalgorithms[42].124depressedbipolarpatientsre-
ceiving maintenance treatment with lithium were randomly
assigned to additional treatment with either lamotrigine or
placebo. After eight weeks, nonresponders were treated with
supplementaryparoxetine20mg/d.Whileadditionoflamot-
rigineprovedeﬀectivecomparedtoplaceboatweek8,adding
paroxetine to nonresponders “blunted” this eﬀect, causing
the two groups to demonstrate no signiﬁcant diﬀerences in
MADRS score by week 16. While this might indicate par-
oxetine as a potential eﬃcacious agent, the lack of a second
placebo arm, controlling for the eﬀect of paroxetine, causes
an inability to rule out at least some degree of spontaneous
recovery, unrelated to paroxetine use.
3.2.3. Olanzapine/Fluoxetine Combination. Since the intro-
duction of Symbyax, an olanzapine/ﬂuoxetine combination
(OFC), it has gained widespread use for the treatment of
bipolar depression, becoming the ﬁrst treatment to be ap-
proved by the U.S. Federal Drug Administration for this
indication in 2003 [43]. In a double-blind, 8-week, ran-
domized controlled trial published by the Lilly Research
Laboratories the same year, 833 adult bipolar I patients were
randomized to treatment with olanzapine, OFC, or placebo.
Bothtreatmentsweresigniﬁcantly (P<0.001) more eﬀective
thanplaceboinreducingMADRSscores,withcorresponding
therapeutic eﬀect sizes for olanzapine and OFC of 0.32
and 0.68, respectively. OFC proved signiﬁcantly better than
olanzapine alone as of week 4, meeting remission criteria by
the end of the 8-week trial in 48.8% of cases. No major
adverse events were reported, including treatment-emergent
mania/hypomania [33, 34]. Health-related quality of life was
also demonstrated to improve [44]. In another randomized
comparative study of 34 bipolar I and II patients, discussed
earlier, olanzapine/ﬂuoxetine combination showed a signif-
icant decrease in both HAM-D 28 and MADRS ratings
compared to placebo, with no evidence of a signiﬁcant in-
crease in manic symptoms [13]. An additional Lilly Research
Laboratories publication from 2006 compared OFC to
lamotrigine in the acute, 7-week treatment of 410 bipolar I
patients. While OFC demonstrated a signiﬁcant advantage
over lamotrigine in reducing MADRS scores, the overall
eﬀect size was relatively small (P = .002, eﬀect size = 0.24).
Though time to response was signiﬁcantly shorter for OFC-
treated patients (OFC median days = 17 versus lamotrigine
23; P = .01), the response rates—albeit high (OFC, 68.8%
versus LMG, 59.7%; P = .073)—did not signiﬁcantly diﬀer
between both treatment groups. In addition, OFC-treated
patients suﬀered signiﬁcantly more adverse events, including
sedation,weightgain,andtremor,aswellashavingincreased
levels of total cholesterol and triglycerides. Interestingly,
genotyping of SNPs within the dopamine D3 receptor and
histamineH1receptorgeneswassigniﬁcantlyassociatedwith
response to OFC, possibly demonstrating the importance of
the dopaminergic system in the treatment of patients with
bipolar I depression [45].
AnotherstudyworthmentioninginthiscontextisaLilly-
sponsored open-label continuation trial of 114 bipolar pa-
tients in Puerto Rico. The ﬁrst phase of the trial included a 7-
week treatment course with OFC, demonstrating a response
rate of 69% and a remission rate of 59%, in accordance with
earlier ﬁndings. Responders were then randomized to either
OFCcontinuationorolanzapinealonefor12weeks,showing
maintenance of response to be signiﬁcantly higher for the
OFCgroupthantheolanzapinegroup(31.3%versus12.5%).
Metabolic adverse eﬀects were highly prevalent, with 33%
of the OFC-treated patients gaining over 7% of their body
weight over the 4-month course [46].
4. Discussion
It is astounding how, despite numerous trials and meta-
analyses conducted on the subject in recent years, the role
of antidepressants in the treatment of bipolar depression still
remains unclear. Since the 2004 meta-analysis by Gijsman
et al. [22], demonstrating antidepressants as a whole, and
SSRIs in particular, to be both eﬀective and safe as an add-onDepression Research and Treatment 5
Table 1: Summary of recent studies examining the eﬃcacy of antidepressants in the treatment of acute bipolar depression.
Positive studies Negative studies
Study No. of
participants Drug Comments Study No. of
participants Drug Comments
Antidepressants as monotherapy
Amsterdam and
Shults 2005 [13]
34
(BPI = 32,
BPII = 2)
Fluoxetine,
olanzapine/ﬂuoxetine
combination
No placebo
control
McElroy et al.
2010
(EMBOLDEN
II) [14]
740
(BPI = 478,
BPII = 262)
Paroxetine
Parker et al.
2006 [16] 10 BPII Escitalopram Small sample
size
Agosti and
Stewart 2007
[21]
70 BP II Imipramine,
phenelzine
No
signiﬁcance
demonstrated
Amsterdam and
Shults 2008 [17] 83 BPII Venlafaxine No placebo
control
Amsterdam and
Shults 2010 [15] 148 BPII Fluoxetine No placebo
control
Antidepressants with mood stabilizers
Schaﬀer et al.
2006 [27] 20 Citalopram
Small sample
size, no
placebo
control
Sachs et al. 2007
[29]
366
(BPI = 240,
BPII = 114)
Paroxetine,
bupropion
Fonseca et al.
2006 [28] 20 Escitalopram
Small sample
size, no
placebo
control
Sidor et al. 2011
[32]
1,034 (Meta-
Analysis)
Fluoxetine,
paroxetine,
bupropion,
imipramine
Tamayo et al.
2009 [46] 114 Olanzapine/ﬂuoxetine
combination
Conducted by
Lilly Research
Laboratories
Pilhatsch et al.
2010 [41] 40 Paroxetine,
amitriptyline
No placebo
control
Perlis et al. 2010
[45] 410 Olanzapine/ﬂuoxetine
combination
Conducted by
Lilly Research
Laboratories
therapy for acute bipolar depression, many studies published
since showed evidence both supporting and contradicting
these results.
4.1. Antidepressant Eﬃcacy. A marked disparity exists bet-
ween the results of studies examining the eﬃcacy of antide-
pressants in acute bipolar depression, whether as monother-
apy or as an adjunct to mood stabilizers (Table 1). Although
as a whole more studies concluded in favor of antidepressant
treatment eﬃcacy in both modalities, most of them suﬀered
major methodological disadvantages, such as lack of a
placeboarm[13,15,17,27,28,41],smallsamplesize[16,27,
28], or substantial industry involvement [44–46]. However,
although industry-sponsored, it is hard to dismiss the sig-
niﬁcant eﬃcacy demonstrated for the ﬁrst FDA-approved
therapy for bipolar depression, olanzapine/ﬂuoxetine com-
bination (OFC), showing an eﬀect size of 0.68 compared to
0.32 of olanzapine alone [33, 34]. On the other hand, the two
studies showing lack of antidepressant eﬃcacy were based
on results of the STEP-BD [29] and EMBOLDEN II trials
[14], both of high methodological quality in terms of ran-
domization, control, blinding, and sample size. Thus, a more
recent meta-analysis, published in 2011 and incorporating
the results of recent trials, showed no signiﬁcant eﬃcacy of
antidepressants in the treatment of acute bipolar depression
[32]. In an attempt to address the discrepancy between the
positive eﬀects of antidepressants demonstrated by Gijsman
et al. [22] and more recent results, the authors pointed out to
potential ﬂaws in the analysis, among which is the inclusion
of studies causing bias for antidepressant eﬃcacy [32]. How-
ever, several issues need to be taken into account, prior to
regarding antidepressants as ineﬀective for this indication.
First is the fact that—although not statistically signiﬁcant—
antidepressant eﬃcacy in the more recent meta-analysis was
very close to demonstrating signiﬁcance in both induction
of remission (95% CI 0.99–1.40; P = .06) and response
(95% CI 0.98–1.47; P = .09) [32]. Second is the fact that
the largest negative trial incorporated in the meta-analysis,
based on STEP-BD results [29], included a substantial nega-
tive treatment eﬀect, favoring placebo over antidepressants.
Although such data is unavailable, it is quite possible that
correcting for this eﬀect might have shifted the conﬁdence
interval in the meta-analysis slightly, rendering antidepres-
sants signiﬁcantly superior to placebo, even if not by much.6 Depression Research and Treatment
Table 2: Summary of recent studies examining the risk of manic/hypomanic switch following the use of antidepressants in the treatment of
acute bipolar depression.
Increased risk of switch No increased risk of switch
Study No. of
participants Drug Comments Study No. of
participants Drug Comments
Antidepressants as Monotherapy
Amsterdam and
Shults 2005 [13]
34
(BPI = 32,
BPII = 2)
Fluoxetine,
olanzapine/ﬂuoxetine
combination
No Placebo
Control
Parker et al.
2006 [16] 10 BPII Escitalopram Small sample
size
Agosti and
Stewart 2007
[21]
70 BP II Imipramine,
phenelzine
No valid tool
used to assess
switch
Amsterdam and
Shults 2008 [17] 83 BPII Venlafaxine
Compared to
Lithium, no
placebo
control
McElroy et al.
2010
(EMBOLDEN
II) [14]
740
(BPI = 478,
BPII = 262)
paroxetine
Amsterdam and
Shults 2010 [15] 148 BPII Fluoxetine
No placebo
control,
subsyndromal
hypomania in
19.6%
Antidepressants with mood stabilizers
Post et al. 2006
[40] 174 Venlafaxine
15%; no
placebo
control
Schaﬀer et al.
2006 [27] 20 Citalopram
Small sample
size, no
placebo
control
Truman et al.
2007 [30]
366
(BPI = 240,
BPII = 114)
Paroxetine,
bupropion
By self-report
only
Fonseca et al.
2006 [28] 20 Escitalopram
Small sample
size, no
placebo
control
Amsterdam and
Shults 2010 [15]148 BPII Fluoxetine
No placebo
control,
subsyndromal
hypomania in
19.6%
Sachs et al. 2007
[29]
366
(BPI = 240,
BPII = 114)
Paroxetine,
bupropion
Perlis et al. 2010
[45] 410
Olanzapine/ﬂuoxetine
combination,
lamotrigine
Conducted by
Lilly Research
Laboratories
Sidor et al. 2011
[32]
1,034
(Meta-
Analysis)
Fluoxetine,
paroxetine,
bupropion,
imipramine
Finally, the heterogeneous inclusion of patients treated
with various “mood stabilizers,” some of them possessing
antidepressantactivity,suchasquetiapine[14]orolanzapine
[33,34],maycauseanadditionaldiﬃcultyininterpretingthe
data; further trials of antidepressant augmentation of a more
homogeneous “mood stabilizer” are advised.
4.2. The Risk of a Manic/Hypomanic Switch. The majority
of recent studies do not demonstrate a signiﬁcant risk of
manic/hypomanic switch as a result of antidepressant treat-
ment in acute bipolar depression, both as monotherapy and
in conjunction with a mood stabilizer (Table 2). Only the
use of very “liberal” criteria, such as self-report [30]o r
an interviewer impression of “subsyndromal hypomania”
(deﬁned as an episode lasting 3 or less days with 4 symptoms
or more, or as an episode lasting 4 days or more with 3
symptoms or less) [15], has succeeded in providing evidence
for an increased risk of switch as result of SSRI treatment.Depression Research and Treatment 7
While a somewhat higher risk was associated with the use of
the SNRI venlafaxine [40] or tricyclic antidepressants [22],
data interpretation is diﬃcult due to the lack of comparison
to placebo [40], as well as the lack of use of objective clinical
scales to assess an aﬀective switch [22]. Indeed, considerable
inconsistency exists between studies regarding the deﬁnition
of such a switch, including the use of diﬀerent scales, such as
the Clinical Global Impression for Bipolar Disorder (CGI-
BP) [40] or the Young Mania Rating Scale (YMRS), or
using diﬀerent cutoﬀ scores for mania or hypomania on the
scale, such as a YMRS score of 16 [14], 14 [31], 13 [40],
12 [29], or 8 [15]. The result is making data applicability
to clinical practice diﬃcult. However, while the overall risk
of an aﬀective switch during acute treatment with an antide-
pressant is probably low, especially with the use of SSRIs or
bupropion, some patient populations have been identiﬁed as
b e i n gm o r ep r o n et ot h i ss i d ee ﬀect, including those with the
bipolar I subtype compared to bipolar II [31], rapid-cycling
patients [40], and patients with a shorter duration of illness
and a history of multiple antidepressant trials [30].
4.3. Therapeutic Implications
4.3.1. Diagnosis. If antidepressants are indeed redundant in
the treatment of bipolar depression, it should have a direct
impact on several aspects of the care of depressed bipolar
patients, as well as depressed patients in general. First is the
heightened importance of reaching the correct initial diag-
nosis of bipolar depression, often misdiagnosed as unipo-
lar depression upon ﬁrst presentation [47]. While recent
attempts have failed in providing unequivocal support for
the role of misdiagnosed bipolar disorder as a major cause
for refractory depression [48], clinicians have nevertheless
been urged to be more sensitive to “soft” bipolar signs when
making a diagnosis, including “lowering the threshold” for
hypomanic episodes [49]. A timely diagnosis of bipolar dis-
order has been shown to correlate with better outcomes [50–
52] as well as reduced healthcare costs [53, 54], illustrating
the importance of making a correct diagnosis as early as pos-
sible.
4.3.2. Assessment of Treatment Response. Aside from the im-
portance of making a correct diagnosis, several other factors
have been suggested as relevant in treating patients suﬀering
from bipolar depression. One is the identiﬁcation of clinical
factors potentially associated with antidepressant resistance,
including the severity of the current episode, presence of
melancholic features, current suicidal risk, and psychiatric
comorbidity,includingsocialphobia[55].Adequatelyassess-
ing the presence of other comorbid conditions, such as sub-
stance use, is crucial, especially in light of the extensive eﬀect
they may have on treatment response [56] and the risk of af-
f e c t i v es w i t c h[ 57].
Following initiation of treatment, assessment of response
poses another challenge. In one large trial, early improve-
ment of depressive symptomatology did not appear to be a
reliablepredictorofeventualresponseorremissionduetoan
unacceptably high false-positive rate. However, the absence
of early improvement appeared to be a highly reliable pre-
dictor of eventual nonresponse, demonstrating the need for
close monitoring of patient status during the initial phase of
treatment [58]. Adherence should also be closely monitored,
as certain factors have been associated with nonadherence
in bipolar disorder, including selected patient factors, such
as demographic features, symptom severity and phase of
illness, presence of past suicide attempts, psychiatric comor-
bidity, illness and treatment duration, and relationship with
providers, as well as treatment factors, including type and
intensity of treatment [59].
4.3.3. Extent and Duration of Treatment. Another issue in
the treatment of acute bipolar depression is the duration
of treatment. In a trial conducted as part of the Systematic
Treatment Enhancement Program for Bipolar Disorder
(STEP-BD) study, patients responding to treatment with
antidepressants plus mood stabilizers, and euthymic for 2
months, were randomly assigned to antidepressant continu-
ation versus discontinuation. After a follow-up period of 1–3
years, antidepressant continuation showed a mildly delayed
depressive episode relapse (HR = 2.13 [1.00–4.56]) and tren-
dedtowardlessseveredepressivesymptoms(meandiﬀerence
= −1.84 [95% CI, −0.08 to 3.77]), without increased manic
symptoms [60]. Other trials showed comparable results [61,
62], providing evidence to support recommendations for
continuing long-term antidepressant treatment for respon-
sive patients. However, the full consequences of long-term
antidepressant treatment, including the potential of increas-
ing the risk of an aﬀective switch, are out of the scope of this
discussion. The goal of treatment should be full remission, as
subsyndromaldepressivesymptomshavebeendemonstrated
to result in marked functional impairment [63].
In conclusion, it is worth noting that bipolar disorder is
a complex condition, requiring a multimodal approach. The
tools used in the treatment of bipolar disorder include vari-
ous pharmacological treatments, including antidepressants,
mood stabilizers, and antipsychotics, nonpharmacological
treatment modalities, such as electroconvulsive therapy and
transcranial magnetic stimulation, as well as psychothera-
peutic approaches. Proper integration of all available modal-
ities is necessary for optimal treatment response.
4.4. Impact on PrescribingGuidelines. Probably in light of the
inconclusive nature of the evidence, a review of guidelines
published in recent years has not revealed major changes in
the recommendations regarding antidepressant treatment.
While the American Psychiatric Association (APA) guideline
for the treatment of bipolar disorder was not updated since
2005 [64], it did include a recommendation of olanzapine/
ﬂuoxetine combination as a ﬁrst-line option in the treatment
of bipolar depression. At the same time, evidence for the
eﬃcacy of an antidepressant with adjunctive mood stabilizer
was described as modest, while prescription of antidepres-
sants in the absence of a mood stabilizer was not recom-
mended for bipolar I patients. In an International Con-
sensus Group (ICG) updated in 2007 [65], antidepressant
treatment for bipolar I depression was indicated only “as
an acute adjunct to treatment, with no additional beneﬁt8 Depression Research and Treatment
in the long-term treatment of bipolar depression.” Evidence
supportingeﬃcacyinbipolarIIdepressionhasbeenassigned
to the lowest category. The 2009 NICE guideline [66]d o e s
include a ﬁrst-line treatment option with an antidepressant
for moderate-severe depression, albeit with a concurrent
antimanicagentonly,asdoesthe2009CanadianNetworkfor
Mood and Anxiety Treatments (CANMAT) guideline [67].
Recommendations of the British Association of Psychophar-
macology (BAP) of the same year have been slightly more
liberal,inallowingantidepressantmonotherapyasaﬁrst-line
option for patients with no past evidence of mania, yet with
a recommendation for gradual discontinuation of treatment
after 12 weeks [68].
In a 2010 update of the World Federation of Societies of
Biological Psychiatry (WFSBP) guideline on the treatment
of acute bipolar depression, only the olanzapine/ﬂuoxetine
combination has been approved as a ﬁrst-line therapy for
this indication. There were no additional recommendations
regarding antidepressant therapy, aside for mentioning pos-
sible eﬃcacy in bipolar II patients [69].
In summary, while the major trend in recent years has
been the adoption of quetiapine monotherapy as a ﬁrst-
line agent, most guidelines still advocate the use of antide-
pressants as potential ﬁrst-line agents in the acute treatment
of bipolar depression, in adjunction to mood stabilizers.
Speciﬁc references were made for the SSRIs paroxetine [67,
69] and sertraline [65, 69], the dopamine-norepinephrine
reuptake inhibitor bupropion [65, 67, 69] and the serotonin-
norepinephrine reuptake inhibitor venlafaxine [65, 67, 69].
5. Conclusions
Studies conducted in recent years have failed to demonstrate
signiﬁcant beneﬁcial eﬀects of antidepressants in the treat-
ment of acute bipolar depression. The rate of manic/hypo-
manic switch is probably low, especially with concurrent
use of mood stabilizers. However, the considerable disparity
between studies should prompt further large-scale, long-
term, double-blind, randomized clinical trials, including
comparison between various classes of antidepressants.
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